2 Sympathy Plays To Watch For In The Wake Of Biogen’s Positive Alzheimer’s Drug Data
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.
Check Out What Whales Are Doing With LLY
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
US Agency EEOC Files Lawsuit Against Eli Lilly Over Nationwide Age Discrimination
The U.S. Equal Employment Opportunity Commission (EEOC) accused Eli Lilly And Co (NYSE:LLY) of illegally refusing to hire older workers for…
Peering Into Eli Lilly’s Recent Short Interest
Eli Lilly's (NYSE:LLY) short percent of float has risen 8.2% since its last report. The company recently reported that it has 5.18 million shares sold short, which is 0.66% of all regular shares that are available for trading.
Eli Lilly Whale Trades Spotted
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Eli Lilly Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.
FDA Approves Lilly’s Retevmo, the First and Only RET Inhibitor For Solid Tumor Indications
The FDA has approved Eli Lilly And Co’s (NYSE:LLY) Retevmo (selpercatinib, 40 mg & 80 mg capsules) for solid tumors. The…
UBS Upgrades Eli Lilly to Buy, Announces $363 Price Target
UBS analyst Navin Jacob upgrades Eli Lilly (NYSE:LLY) from Neutral to Buy and announces $363 price target.
FDA Approves Lilly’s Retevmo for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Eli Lilly and Company (NYSE: LLY) today announced the U.S.